Miracor Medical Systems Appoints International Scientific Advisory Council

“I look forward to supporting Miracor to make PiCSO therapy available in the US.”
(Dr. Gregg W. Stone, Columbia University, New York)

Miracor - PiCSO Impulse System (Graphic: Business Wire)

VIENNA--()--Miracor Medical Systems announced today that it has appointed an international Scientific Advisory Council consisting of leading clinicians to support the further clinical and technological progress of the PiCSOAMI Impulse System.

The internationally recognized leaders in medical research joining Miracor’s Scientific Advisory Council are:

  • Adrian P. Banning, MD, FRCP, FESC; Professor of Interventional Cardiology and Consultant Cardiologist at the John Radcliffe Hospital in Oxford, United Kingdom;
  • Malte Kelm, MD, FESC; Professor and Chair of the Division of Cardiology, Pulmonary Diseases, and Vascular Medicine at the University Hospital Düsseldorf, Germany;
  • Werner Mohl, MD, PhD; Inventor of the PiCSO concept and Professor and academic surgeon at the Medical University of Vienna, Austria;
  • Tienush Rassaf, MD, FESC; W2 Heisenbergprofessor for Myocardial Infarction of the German Research Foundation at the Heinrich-Heine-University Düsseldorf and Director of Cath Labs of the Department of Cardiology at the University Hospital Düsseldorf, Germany. Appointed Head and Director of the Department of Cardiology at the West-German Heart and Vessel Center in Essen, Germany (to commence in August 2015);
  • Gregg W. Stone, MD, FACC, FSCAI; Professor of Medicine at the Columbia University Medical Center, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital, and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation in New York, NY, USA;
  • Azfar G. Zaman, MD, BSc, MBChB, FRCP; Professor of Cardiology, Consultant Interventional Cardiologist, and Head of Coronary Intervention and Director of the Cardiac Catheter Laboratories at the Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom.

“We are delighted that these outstanding clinicians and scientists will provide invaluable input to the company’s clinical and R&D strategies.” says Ludwig Gold, CEO of Miracor Medical Systems; “Miracor is in a very exciting phase with substantial clinical and commercial progress and ongoing internationalization. I’m convinced that the Scientific Advisory Council will contribute substantially to further expand the successful establishment of the PiCSOAMI Therapy in daily clinical practice.”

“Miracor has made significant progress in demonstrating the effectiveness of PiCSOAMI Therapy and its potential benefits in the treatment of patients with acute myocardial infarction (AMI).” said Dr. Gregg W. Stone; “Emerging experience in Europe confirms that the integration of PiCSOAMI Therapy in the existing treatment pathways of primary PCI is feasible” he added. “I look forward to being part of the efforts to further prove the clinical utility of PiCSO, and to supporting the company to make this therapy available in the US.”

Reducing patient mortality caused by necrosis of myocardial tissue after treatment with PCI was a hot topic at this year’s EuroPCR in Paris on May 17-20, one of the most important international congresses in interventional cardiology. Recent clinical data from the Prepare RAMSES study, published in EuroPCR’s Eurointervention journal during the congress, further demonstrates that PiCSO may significantly reduce infarct size and enhance myocardial recovery in patients presenting with acute ST-Segment Elevation Myocardial Infarction (STEMI). (Follow link to publication).

See also video interviews with Dr. Azfar G. Zaman and Dr. Malte Kelm on the PiCSOAMI Therapy, recorded at EuroPCR by Radcliffe Cardiology. (Follow link to videos)

About Miracor Medical Systems GmbH

Miracor Medical Systems GmbH (www.miracormedical.com) is an Austrian medical device company developing disruptive solutions to treat severe heart diseases; striving to bring back cardiac patients to normal life. Miracor develops and commercializes the PiCSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, a technology platform designed to improve clinical outcome of patients with impaired cardiac function. So far, Miracor has raised over EUR 24 million in venture capital and public funding. Major investors include Earlybird Venture Capital, Delta Partners, SHS, BioMedInvest, and aws Founders Fund.

The Miracor PiCSOAMI (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System is designed to treat acute ST-Segment Elevation Myocardial Infarction (‘STEMI’) patients and Non-ST-Segment Elevation Myocardial Infarction (‘NSTEMI’) patients by improving myocardial perfusion in complement with percutaneous coronary intervention (PCI). PiCSOAMI is applied during PCI and designed to intermittently block the coronary sinus, a large vessel that collects blood from the heart muscle (myocardium), thereby increasing perfusion of the myocardium and reducing injury resulting from myocardial infarction.

# # # # #

NOTE: The CE marked PICSO® Impulse System is approved for sale in Europe.

It is currently not approved for use in the United States.

Contacts

Miracor Medical Systems GmbH
Cajetan von König
Director Sales & Marketing
cvkoenig@miracormedical.com
Phone: +43 664 8829 7686

Release Summary

Miracor Medical Systems announced that it has appointed an international Scientific Advisory Council to support the further clinical and technological progress of the PiCSO Impulse System.

Contacts

Miracor Medical Systems GmbH
Cajetan von König
Director Sales & Marketing
cvkoenig@miracormedical.com
Phone: +43 664 8829 7686